57 completed, 18 active not recruiting, 12 recruiting, 12 terminated. 110 Phase 2, 27 Phase 1, 2 Phase 3.
Follow Medulloblastoma: new trials by email Literature Review of Medulloblastoma trials Research Report on Medulloblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma administration of axitinib in combination with etoposide - Medulloblastoma, Ependymoma | Phase 1 / Phase 2 | Recruiting | Assistance Publique Hopitaux De Marseille | 40 | 2032-02-01 | 2026-11-12 |
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-11-30 | 2026-10-30 |
| Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma Arsenic Trioxide (ATO), ETOPOSIDE - Study, Cisplatin - Medulloblastoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 78 | 2026-10-01 | 2026-10-02 |
| Pharmacoscopy for Patients With Refractory Primary Brain Tumors Pharmacoscopy 1.0 - Brain (Nervous System) Cancers, Glioblastoma | Phase 2 | Recruiting | University of Zurich | 40 | 2026-09-11 | 2026-09-21 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| Digoxin Medulloblastoma Study Digoxin - Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 23 | 2026-01-15 | 2026-11-04 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-07-18 | 2026-08-24 |
| PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications PLX038 - Glioma, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 146 | 2024-01-31 | 2026-11-06 |
| Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma Surgical resection, Ommaya/VPS, Methotrexate - Medulloblastoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 130 | 2022-12-20 | 2026-09-15 |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma Sonidegib, Cisplatin, Lomustine - Medulloblastoma | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 20 | 2022-11-11 | 2025-10-23 |
| Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study [18F]DPA714 - Brain Tumor, Medulloblastoma | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 22 | 2022-07-05 | 2026-10-19 |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations ENV-101 (taladegib) - Solid Tumors With PTCH1 Loss-of-function Mutations | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 20 | 2022-05-24 | 2026-03-05 |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor | Phase 2 | Completed | John Yu | 50 | 2021-09-30 | 2026-07-10 |
| 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma 177Lu-DTPA-omburtamab - Medulloblastoma, Childhood | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 2 | 2021-09-30 | 2023-10-06 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 15 | 2021-06-03 | 2023-03-24 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-11-13 |
| Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy AloCELYVIR - Diffuse Intrinsic Pontine Glioma, Medulloblastoma, Childhood, Recurrent | Phase 1 / Phase 2 | Active not recruiting | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | 13 | 2021-04-19 | 2024-12-27 |
Showing 20 of 110. Sign in to see all of them.
Ependymoma (43) · Neuroblastoma (41) · Central Nervous System Neoplasms (39) · Glioma (38) · Brain Neoplasms (29) · Osteosarcoma (25) · Astrocytoma (24) · Rhabdomyosarcoma (24) · Sarcoma (23) · Familial ependymoma (20) · Rhabdoid Tumor (20) · Glioblastoma (19) · Neuroectodermal Tumors, Primitive, Peripheral (19) · Neuroectodermal Tumors, Primitive (18)
Neoplasms by Histologic Type (110) · Neoplasms, Glandular and Epithelial (110) · Neoplasms, Nerve Tissue (110) · Neoplasms, Neuroepithelial (109) · Neuroectodermal Tumors (107) · Neoplasms (104) · Neoplasms, Germ Cell and Embryonal (104) · Neuroectodermal Tumors, Primitive (92) · Neoplasms by Site (74) · Glioma (72) · Nervous System Diseases (67) · Nervous System Neoplasms (65) · Central Nervous System Diseases (43) · Brain Diseases (42) · Neoplasms, Connective and Soft Tissue (33)
Cyclophosphamide (20) · Temozolomide (17) · Cisplatin (14) · Etoposide (14) · Radiotherapy (14) · Carboplatin (11) · Vincristine (11) · Irinotecan (10) · Magnetic Resonance Spectroscopy (10) · Filgrastim (9) · Lomustine (6) · Peripheral Blood Stem Cell Transplantation (6) · Phantoms, Imaging (6) · X-Rays (6) · Bevacizumab (5)
National Cancer Institute (NCI) (25) · Children's Oncology Group (4) · Duke University (4) · St. Jude Children's Research Hospital (4) · Sue O'Dorisio (4) · Giselle Sholler (3) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Pediatric Brain Tumor Consortium (3) · Eli Lilly and Company (2) · Herbert Irving Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Nationwide Children's Hospital (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · Washington University School of Medicine (2)
United States (87) · Canada (19) · Puerto Rico (19) · Australia (18) · France (16) · Spain (13) · Italy (10) · United Kingdom (10) · Germany (9) · Switzerland (9) · Netherlands (7) · China (4) · Denmark (4) · New Zealand (4) · Sweden (4)
Darell D. Bigner, MD, PhD (3) · Amar Gajjar (2) · Charles S. Hesdorffer, MD (2) · Giselle Sholler, MD (2) · Maryam Fouladi (2) · Maryam Fouladi, MD (2) · Adam S Levy (1) · Aditi Bagchi, MD, PhD (1) · Alice Lee (1) · Alok Kothari, M.D. (1) · Amar Gajjar, MD (1)
PMID 31401903, PMID 26169613, PMID 40073837, PMID 40721826, PMID 40967259, PMID 11835236, PMID 16408203, PMID 16532433, PMID 16549835, PMID 17019740, PMID 17610262, PMID 18447671, PMID 18623206, PMID 18989154, PMID 20943374, PMID 28153957, PMID 29181270, PMID 31838007, PMID 33025730, PMID 33591402, PMID 33823018, PMID 34168987, PMID 34171339, PMID 34486544, PMID 34540703, PMID 35353553, PMID 35395680, PMID 36291912, PMID 37883081, PMID 38815151, PMID 38935895, PMID 39298716, PMID 40086048, PMID 41166674, PMID 42686334, PMID 42788739, PMID 42853672, PMID 42867148
U10CA180886 (15), U10CA098543 (5), U01CA081457 (4), R01CA167632 (3), UM1CA081457 (3), 2023 (2), 2016 (1), 2019 (1), P30CA008748 (1), P30CA022453 (1), P30CA033572 (1), P30CA086862 (1), P30CA124435 (1), R01CA187079 (1), R01CA229646 (1)